Drugs / SynOV1.1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04612504 | Jun 2022 → Dec 2023 | hepatocellular carcinoma | Beijing Syngentech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SynOV1.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04612504 ↗ |
| Route | Other | “administered intratumorally” NCT04612504 ↗ |